<DOC>
	<DOCNO>NCT01750697</DOCNO>
	<brief_summary>This Phase IIa international multicenter , open-label , uncontrolled study evaluate safety pharmacokinetics rituximab ( MabThera/Rituxan ) pediatric participant severe granulomatosis polyangiitis ( GPA ) microscopic polyangiitis ( MPA ) . Participants receive rituximab 375 milligram per square meter ( mg/m^2 ) intravenously ( IV ) Days 1 , 8 , 15 22 .</brief_summary>
	<brief_title>A Phase IIa Study Intravenous Rituximab Pediatric Participants With Severe Granulomatosis With Polyangiitis ( Wegener 's ) Microscopic Polyangiitis</brief_title>
	<detailed_description />
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis GPA ( EULAR/PRINTO/PRES 2008 , Ankara criterion childhood Wegener 's granulomatosis ) diagnosis MPA ( accord Chapel Hill Consensus Conference ) Newly diagnose participant participant relapse disease accord follow definition : The recurrence new onset potentially organ lifethreatening disease ( i.e . one major Birmingham Vasculitis Activity Score Wegener 's Granulomatosis [ BVAS/WG ] item disease severe enough require treatment cyclophosphamide ) For participant reproductive potential ( male female ) , use reliable mean contraception throughout study participation For eligible participant mandatory prophylactic treatment Pneumocystis jirovecii infection Diagnosis ChurgStrauss syndrome , define Chapel Hill Consensus Conference Limited disease would normally treat cyclophosphamide Severe disease require mechanical ventilation due alveolar hemorrhage Requirement plasmapheresis dialysis screen Incomplete recovery recent surgery le ( &lt; ) 12 week since surgery prior baseline plan within 24 week baseline Lack peripheral venous access Pregnancy breastfeed Evidence significant uncontrolled concomitant disease , disorder condition , investigator 's opinion , would preclude interfere participation participant Primary secondary immunodeficiency ( history currently active ) , include know history human immunodeficiency virus ( HIV ) infection Evidence active tuberculosis ( participant receive chemoprophylaxis latent tuberculosis infection eligible study ) Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization treatment IV antiinfective agent within 4 week baseline completion oral antiinfective agent within 2 week prior baseline . Entry study may reconsider infection fully resolve History deep space/tissue infection within 24 week prior baseline History serious recurrent chronic infection History cancer ( except basal cell squamous cell carcinoma skin excise cure ) Currently active alcohol drug abuse history alcohol drug abuse History severe allergic anaphylactic reaction biologic agent know hypersensitivity component rituximab murine proteins Treatment rituximab biologic B cell−targeted therapy ( e.g. , anti Cluster Differentiation [ CD ] 19 , antiCD20 , antiCD22 , antiBlymphocyte stimulator [ BLys ] /Bcell activate factor [ BAFF ] ) within 6 month prior baseline visit Previous treatment antialpha 4 integrin antibody costimulation modulator Previous treatment celldepleting therapy , include , limited , investigational agent ( e.g. , alemtuzumab , antiCD4 , antiCD5 , antiCD3 , antiCD11a ) Receipt oral IV cyclophosphamide within previous 4 month prior baseline visit Receipt infliximab within 3 month , adalimumab within 2 month etanercept within 1 month prior baseline visit Treatment investigational agent within 28 day baseline 5 halflives investigational drug ( whichever longer ) Receipt live attenuate vaccine within 28 day prior baseline Intolerance contraindication IV glucocorticoid Positive serum human chorionic gonadotropin measure screen positive pregnancy test prior first rituximab infusion participant childbearing potential Positive test hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) , hepatitis B virus ( HBV ) , hepatitis C serology Level Immunoglobulin ( Ig ) M low limit normal agespecific reference range Level IgG 5.65 milligram per milliliter Absolute neutrophil count &lt; 1.5 × 10^3 per microliter platelet count &lt; 130 × 10^3 per microliter Estimated Glomerular Filtration Rate &lt; 15 milliliter per minute per 1.73 m^2 Alanine aminotransferase aspartate aminotransferase level great 2.5 time upper limit normal ( age sex ) attribute underlying granulomatosis polyangiitis ( GPA ) microscopic polyangiitis ( MPA )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>